(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 6.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Jazz Pharmaceuticals's revenue in 2026 is $4,601,233,000.On average, 23 Wall Street analysts forecast JAZZ's revenue for 2026 to be $312,109,286,216, with the lowest JAZZ revenue forecast at $289,778,671,728, and the highest JAZZ revenue forecast at $327,948,443,004. On average, 23 Wall Street analysts forecast JAZZ's revenue for 2027 to be $331,129,257,277, with the lowest JAZZ revenue forecast at $297,049,104,352, and the highest JAZZ revenue forecast at $358,912,696,233.
In 2028, JAZZ is forecast to generate $362,547,912,545 in revenue, with the lowest revenue forecast at $299,645,687,432 and the highest revenue forecast at $425,904,539,697.